Entrada Says First Cohort of ENTR-601-45 Phase 1/2 Trial Shows 'Positive' Safety Results in Duchenne Muscular Dystrophy

08:13 AM EDT, 10/14/2026 (MT Newswires) -- Entrada Therapeutics (TRDA) said Wednesday that the first cohort of its phase 1/2 trial of ENTR-601-45 for Duchenne muscular dystrophy showed "positive" safety and tolerability results. The first cohort met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg, the company said. The secondary objectives showed a 0.10% mean increase in dystrophin production compared with baseline in treated participants at the initial dose of 5 mg/kg. No renal safety concerns were observed, and all participants advanced to the open-label phase, the company said. The second cohort's enrollment is complete, and dosing at 10 mg/kg is ongoing, the company said, adding that data from the second cohort are expected in H1, with data from the third cohort to follow.